| Jared Eldon Roberts, MD | |
|
5323 Harry Hines Blvd, Dallas, TX 75390-7201 | |
| (214) 645-2400 | |
| Not Available |
| Full Name | Jared Eldon Roberts |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 5323 Harry Hines Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629494935 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | S5483 (Texas) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | S5483 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jared Eldon Roberts, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7201 Ph: () - | Jared Eldon Roberts, MD 5323 Harry Hines Blvd, Dallas, TX 75390-7201 Ph: (214) 645-2400 |
News Archive
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
The Hospital Cl-nic of Barcelona presented today the results of the telemedicine program "Hospital VIHrtual", coordinated by Dr. Felipe Garcia and Dr. Agata Le-n, from the Hospital Cl-nic Service of Infectious Diseases directed by Dr. Josep M - Gatell.
EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of its outstanding warrants. Pursuant to these agreements, the Company issued 1,441,743 ordinary shares in the form of American Depositary Shares in exchange for 4,558 senior debentures (equivalent to USD 4,558,000) and 986,965 warrants, reducing the current outstanding debt by USD 4.6 million to USD 10.5 million.
Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).
The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease.
› Verified 5 days ago